Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))
Mach F., Baigent C., Catapano AL., Koskinas KC., Casula M., Badimon L., Chapman MJ., De Backer GG., Delgado V., Ference BA., Graham IM., Halliday A., Landmesser U., Mihaylova B., Pedersen TR., Riccardi G., Richter DJ., Sabatine MS., Taskinen MR., Tokgozoglu L., Wiklund O., Nibouche D., Zelveian PH., Siostrzonek P., Najafov R., van de Borne P., Pojskic B., Postadzhiyan A., Kypris L., Špinar J., Larsen ML., Eldin HS., Viigimaa M., Strandberg TE., Ferrieres J., Agladze R., Laufs U., Rallidis L., Bajnok L., Gudjonsson T., Maher V., Henkin Y., Gulizia MM., Mussagaliyeva A., Bajraktari G., Kerimkulova A., Latkovskis G., Hamoui O., Slapikas R., Visser L., Dingli P., Ivanov V., Boskovic A., Nazzi M., Visseren F., Mitevska I., Retterstol K., Jankowski P., Fontes-Carvalho R., Gaita D., Ezhov M., Foscoli M., Giga V., Pella D., Fras Z., Perez de Isla L., Hagstrom E., Lehmann R., Abid L., Ozdogan O., Mitchenko O., Patel RS., Windecker S., Aboyans V., Collet JP., Dean V., Fitzsimons D., Gale CP., Grobbee D., Halvorsen S., Hindricks G., Iung B., Juni P., Katus HA., Leclercq C., Lettino M., Lewis BS., Merkely B., Mueller C., Petersen S., Petronio AS., Roffi M., Shlyakhto E., Simpson IA., Sousa-Uva M., Touyz RM.
© 2019 [The Author/The Authors] In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.